Macimorelin
A Phase III clinical trial showed that oral macimorelin was effective
for the diagnosis of adult GHD with 82% sensitivity and 92%
sensitivity at an ideal cutoff point of 2.7 GH / mL, comparable to the
GHRH and arginine test [29]. Another phase Clinical trial III was
completed in 2016, to compare its effectiveness with the insulin
tolerance test (ClinicalTrial.gov Identi fi c: NCT02558829), and AEterna
Zentaris announced the search for the approval of macimorelin for this
indication by the FDA and by the European Medicines Agency in March
2017. A Phase II clinical study for the treatment of cancer cachexia is
also underway (ClinicalTrial.gov Identi fi rer: NCT01614990).